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Ample evidence suggests that a-synuclein is
released from cells and propagated from one area
of the brain to others via cell-to-cell transmission. In
terms of their prion-like behavior, a-synuclein propa-
gation plays key roles in the pathogenesis and pro-
gression of a-synucleinopathies. Using a-synuclein-
enriched models, we show that mesenchymal stem
cells (MSCs) inhibited a-synuclein transmission by
blocking the clathrin-mediated endocytosis of extra-
cellular a-synuclein via modulation of the interaction
with N-methyl-D-aspartate receptors, which led to a
prosurvival effect on cortical and dopaminergic neu-
rons with functional improvement of motor deficits in
a-synuclein-enriched models. Furthermore, we iden-
tify that galectin-1, a soluble factor derived from
MSCs, played an important role in the transmission
control of aggregated a-synuclein in these models.
The present data indicated that MSCs exert neuro-
protective properties through inhibition of extracel-
lular a-synuclein transmission, suggesting that the
property of MSCs may act as a disease-modifying
therapy in subjects with a-synucleinopathies.
INTRODUCTION
a-Synuclein consists of 140 amino acids and is found naturally as
an unfolded cytoplasmic protein in neuronal synaptic terminals.
However, overexpression of a-synuclein interrupts normal cell
functions and leads to decreases in neurite outgrowth and
cell adhesion (Takenouchi et al., 2001). a-Synuclein aggregates
comprisingmonomeric, oligomeric intermediate, or fibrillar forms
are thought to be involved in a critical step in the pathogenesis of
Parkinson’s disease (PD) and in other a-synucleinopathies, such
as multiple system atrophy and dementia with Lewy bodies
(Breydo et al., 2012; Ubhi et al., 2011; Uversky et al., 2001b).COligomeric and monomeric a-synuclein have both been de-
tected in cerebrospinal fluid and plasma samples from PD pa-
tients, suggesting that small aggregates of a-synuclein access
the extracellular space (Borghi et al., 2000; El-Agnaf et al.,
2006; Lee et al., 2006). Previous animal and clinical data suggest
that misfolded a-synuclein can be released from cells by exocy-
tosis and transmitted from one brain area to another via cell-to-
cell propagation (Brundin et al., 2010; Hansen et al., 2011).
Although the exact mechanism of a-synuclein transmission
remains unknown, evidence suggests that clathrin-mediated
endocytosis (CME) may have an important role in internalization
of extracellular a-synuclein (Ben Gedalya et al., 2009; Cheng
et al., 2011). As the cargoprotein for endocytosis is usually recog-
nized by a specific receptor on the cell surface (Carroll and Zukin,
2002; Lavezzari et al., 2004; van Dam and Stoorvogel, 2002), it is
possible thata-synucleinmay interactwith cell-surface receptors
that have not been well specified until now. N-methyl-D-aspar-
tate (NMDA) receptor subunits containmotifs that bind the endo-
cytic adaptor protein involved in CME (Lavezzari et al., 2003).
Additionally, a recent study provided the evidence that a-synu-
clein could promote endocytic internalization of surface NMDA
receptors through a mechanism requiring clathrin, suggesting
an interaction between a-synuclein and NMDA receptors (Cheng
et al., 2011). Accordingly, a-synuclein propagation from one area
of thebrain toothers via cell-to-cell transmission is closely related
with disease progression or clinical severity. Thus, strategies tar-
geting modulation of a-synuclein transmission may be important
for the development of future disease- modifying therapies in in-
dividuals with a-synucleinopathies.
Mesenchymal stem cells (MSCs) secrete various cytotropic
factors, including neurotrophic growth factors, chemokines, cy-
tokines, and extracellular matrix protein, which, in turn, exert
neuroprotective effects (Caplan and Dennis, 2006; Kim et al.,
2012; Majumdar et al., 1998). In previous studies, we showed
that MSCs have potent neuroprotective effects through modu-
lation of neuroinflammation, inhibition of apoptotic cell death,
increases in neurogenesis and neuronal differentiation, and
enhancement of autophagy in neurodegenerative models (Kim
et al., 2009; Park et al., 2011, 2012, 2014; Shin et al., 2014).ell Reports 14, 835–849, February 2, 2016 ª2016 The Authors 835
Figure 1. Schematic Illustrations of In Vitro Experiments of a-Synuclein Transmission
(A) SH-SY5Y cells maintained on the bottom of a plate were co-cultured with MSCs using Costar transwell insert and simultaneously were treated with
a-synuclein (aS) fibrils labeled with Alexa Fluor 488.
(B) A donor-acceptor co-culture method. The donor cells labeled with a-synuclein were co-cultured on the top of the acceptor cells transfected with mCherry-
tagged Rab5 (red). Simultaneously, these cells were co-cultured with MSCs using Costar transwell insert.
(C) Bafilomycin was simultaneously added to the SH-SY5Y and MSC co-cultures to exclude lysosomal degradation of a-synuclein by SH-SY5Y.
(D) To exclude internalization of a-synuclein by MSCs, MSCs were pre-treated with dynasore and then co-cultured with SH-SY5Y cells.
(E) The effects of treatment with MK-801, dynasore, Pitstop 2, or TCN 201 on internalization of a-synuclein.
(F) The effects of MSC-CM, Gal-1 siRNA-treated MSC-CM, or Gal-1 treatment on internalization of a-synuclein.In the present study, we evaluated whether MSCs would
inhibit transmission of extracellular a-synuclein and thus exert
a neuroprotective effect using a-synuclein-enriched models.
Furthermore, we determined that galectin-1 (Gal-1), the biolog-
ical molecule secreted from MSCs, plays a crucial role in the
modulation of extracellular a-synuclein transmission.
RESULTS
MSCs Inhibit Internalization and Cell-to-Cell
Transmission of Extracellular a-Synuclein in SH-SY5Y
Cells
When a-synuclein fibrils labeled with Alexa Fluor 488 were
incubated in SH-SY5Y cells, punctate and vesicular patterns of836 Cell Reports 14, 835–849, February 2, 2016 ª2016 The Authorsa-synuclein were revealed in the cytoplasm. Co-culture with
MSCs (Figure 1A) markedly decreased internalization of labeled
a-synuclein fibrils (Figure 2A); however, co-culture with SH-
SY5Y cells had nomodulatory effects on a-synuclein internaliza-
tion (data not shown). A donor-acceptor co-culture method
(Figure 1B) demonstrated that the transfer of a-synuclein from
donor cells to connected acceptor cells occurred in the a-synu-
clein treatment group; however, transmission of a-synuclein
from donor cells to acceptor cells was observed infrequently
in the group of co-cultured with MSCs or endocytosis blocker
(dynasore) (Figure 2B). In order to demonstrate more clearly
the transmission of a-synuclein between cells, we used an assay
based on biomolecular fluorescence complementation (BiFC),
showing that BiFC signals were markedly decreased in the
Figure 2. MSCs Inhibit Internalization and Cell-to-Cell Transmission of Extracellular a-Synuclein
(A) Immunostaining for internalization of labeled a-synuclein (aS, green) in SH-SY5Y cells after treatment with aS or co-culture with MSCs (MSC). Scale bar
represents 10 mm.
(B) A donor-acceptor co-culture method for transmission (white boxed area) of aS from donor cells (green arrows) to connected acceptor cells (red arrows) after
either aS treatment alone, co-culture with MSCs, or dynasore. Scale bar represents 10 mm. DIC, differential interference contrast.
(C) BiFC signals (green) in the MSC or dynasore treatment group compared with the control group. Scale bar represents 20 mm.
(D) Quantification of internalized cytosolic aS and extracellular aS in the culture medium of the aS treatment group, the co-culture group with MSCs, and the
bafilomycin-treated MSC group (n = 3 per group).
(E) Immunostaining for internalization of labeled aS in SH-SY5Y cells co-cultured with MSCs after treatment with either bafilomycin or dynasore. Scale bar
represents 10 mm.
(F) Quantification of cell viability in the aS group, the co-culture group with MSCs, and the bafilomycin-treated MSC group for 3 hr, 24 hr, and 48 hr (n = 3
per group).
All data are presented as means ± SE. *p < 0.05; **p < 0.01.
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MSC or dynasore treatment group compared with the control
group (Figure 2C). Thus, co-culture with MSCs significantly
decreased the levels of internalized cytosolic a-synuclein, with
a concomitant increase in extracellular a-synuclein of culture
medium, compared with those of the a-synuclein treatment
group (Figure 2D). To exclude lysosomal degradation of a-synu-
clein by SH-SY5Y and internalization of a-synuclein by MSCs, a
lysosomal inhibitor (bafilomycin) and dynasore were added to
the SH-SY5Y and MSC co-cultures, respectively (Figures 1C
and 1D). These drugs did not influence a-synuclein internaliza-
tion or change the intracellular and extracellular a-synuclein
levels (Figures 2D and 2E), indicating that soluble factors
secreted from MSCs might be responsible for modulation of
a-synuclein internalization. To exclude the mitogenic prolifera-
tion effects of MSCs, we additionally performed a viability test
using differentiated SH-SY5Y cells that exhibit no immunoreac-
tivity with Ki-67 antibody. Incubation of a-synuclein fibrils for
24 hr and 48 hr decreased SH-SY5Y cell viability, whereas co-
culture with MSCs recovered a-synuclein-induced cell death
(Figure 2F).
MSCs Inhibit CME of Extracellular a-Synuclein Fibrils
through Modulation of Surface NMDA Receptors
We examined the expression and immunoreactivity of clathrin to
determine the role of CME in a-synuclein internalization. When
a-synuclein fibrils were incubated in SH-SY5Y cells, the expres-
sion of clathrin was significantly increased, comparedwith that in
the control. However, co-culutre with MSCs or treatment with
MK-801 (Figures 1A and 1E), a noncompetitive NMDA receptor
antagonist, significantly attenuated the expression of a-synu-
clein-induced clathrin (Figure 3A). Using confocal microscopy,
we confirmed that co-culture with MSCs or treatment with MK-
801 in a-synuclein-treated SH-SY5Y cells markedly decreased
the immunoreactivity of clathrin that was co-localized with
a-synuclein (Figure 3B). Additionally, the expression of early en-
dosome antigen 1 (EEA1) was increased significantly in a-synu-
clein-treated SH-SY5Y cells compared with that in the control.
However, co-culurewithMSCs or treatment with dysnasore (Fig-
ures 1A and 1E) significantly decreased the expression of EEA1,
the level of which corresponded to that of an endocytosis inhib-
itor treatment (Figure 3C). Confocal microscopy showed that co-
culture with MSCs or dynasore treatment in a-synuclein-treated
SH-SY5Y cells markedly decreased the immunoreactivity of
EEA1 that was co-localized with a-synuclein (Figure 3D). When
clathrin-inhibitor (Pitstop 2)-treated SH-SY5Y cells were incu-
bated with a-synuclein (Figure 1E), the expression of intracellular
a-synuclein and EEA1 was significantly decreased compared to
that in only a-synuclein-treated SH-SY5Y cells (Figure 3E). Next,
we identified whether MSCs inhibit the interaction between
a-synuclein and NMDA receptors using extraction of cell-sur-
face membrane. a-Synuclein treatment in SH-SY5Y cells led
to a significant attenuation in the expression of surface NR1
and NR2A subunits relative to control. However, co-culture
with MSCs or MK-801 treatment (Figures 1A and 1E) prevented
a decrease in the expression of a-synuclein-induced NR1 and
NR2A subunits (Figures 3F and 3H). Moreover, immunocyto-
chemical analysis showed that a-synuclein treatment increased
the immunoreactivity of surface NR1 and NR2A subunits that838 Cell Reports 14, 835–849, February 2, 2016 ª2016 The Authorswere co-localized with a-synuclein, whereas MSCs or MK-
801 treatment led to a decrease in immunoreactivity of co-
merged a-synuclein and surface NR1 and NR2A subunits (Fig-
ures 3G and 3I). Additionally, we found that a selective NR1 and
NR2A receptor antagonist (TCN 201) treatment in a-synuclein-
treated SH-SY5Y cells (Figure 1E) significantly increased the
expression of a-synuclein-induced NR1 and NR2A subunits
and attenuated the expression of a-synuclein-induced clathrin
(Figure S1A). An immunoprecipitation assay to clarify the
interaction of a-synuclein and NMDA receptors showed that
a-synuclein treatment increased the amount of NR1 or NR2A
immunoprecipitated with a-synuclein, whereas the amount of
NR1 or NR2A that interacted with a-synuclein in the MSC-
treated group was comparable to that of the control group (Fig-
ure 3J). As expected, treatment with dynasore or MK801 alone
in SH-SY5Y cells had no effect on immunoreactivities or protein
expressions of clathrin, EEA1, NR1, and NR2A (Figures S1B
and S1C).
Identification and Characterization of MSC-Derived
Factors
To determine proteins secreted from MSCs, we collected three
independent samples of fresh medium, SH-SY5Y-conditioned
media (CM), and MSC-CM for two-dimensional (2D)-PAGE and
MALDI-TOF mass spectrometry (MALDI-TOF/MS) proteomics
(Figures 4A and 4B). Of the proteins expressed exclusively in
MSC-CM (Table S1), we selected Gal-1 as a candidate for a-syn-
ucleinmodulation. We identified that Gal-1 was expressed within
MSCs injected intravenously in a-synuclein-inoculated animals
by showing that human-specific nuclear-mitotic-apparatus-pro-
tein (NuMA)-positive cells were co-immunostained with Gal-1
(Figure S2A) and that the expression of this protein was signifi-
cantly increased in MSCs-treated animals (Figure S2B). Next,
we evaluated whether Gal-1 can modulate transmission of
a-synuclein (Figure 1F). Gal-1 treatment in a-synuclein-treated
SH-SY5Y cells led to decreased internalization of labeled a-syn-
uclein (Figure 4C), with a concomitant decrease in expressions
of clathrin and EEA1 as well as increased expression of NR1
(Figure 4D), which was followed by increased neuronal viability
(Figure 4E). When MSCs were treated with Gal-1 small inter-
fering RNA (siRNA) (Figure S2C), Gal-1 siRNA counteracted
the inhibitory effect of MSCs on CME of a-synuclein via NR1
subunit (Figures 4C and 4D). Moreover, SH-SY5Y cell viability
was prominently attenuated in the presence of Gal-1 siRNA-
treated MSC-CM (Figure 4E). However, the intensity of a-synu-
clein aggregates, transmission, and neuronal viability in Gal-1
siRNA-treatedMSC-CMwas not comparable to the correspond-
ing values in fresh medium or SH-SY5Y-CM (Figures 4C–4E),
suggesting that other soluble factors may be involved in extra-
cellular a-synuclein modulation. To investigate the interaction
between Gal-1 and NR1 and NR2A receptors, the membrane
and cytosol lysates were immunoprecipitated with anti-NR1 or
anti-NR2A and then immunoblotted with an antibody against
Gal-1.We found that MSC-CM treatment significantly increased
the amount of Gal-1 immunoprecipitated with NR1 in both
membrane and cytosol fractions, whereas the amount of
Gal-1 that interacted with NR1 and NR2A in the fresh medium
group was comparable to that of the control group (Figure 4F).
Figure 3. MSCs Inhibit CME of Extracellular a-Synuclein Fibrils via Modulation of Surface NMDA Receptors
(A and B) Western blot for clathrin (A) and immunostaining of clathrin that is co-localized with a-synuclein (aS) (B) after aS treatment alone, co-culture with MSCs,
or MK-801 treatment (n = 3 per group). Scale bar represents 10 mm.
(C andD)Western blot for EEA1 (C) and immunostaining of EEA1 that is co-localizedwith aS (D) after either aS treatment alone, co-culture withMSCs, or dynasore
treatment (n = 3 per group). Scale bar represents 10 mm.
(E) Western blot for EEA1 and aS after aS treatment alone, Pitstop 2 treatment, or co-culture with MSC (n = 3 per group).
(F and G) Western blot for NR1 (F) and immunostaining of NR1 that is co-localized with aS (G) after either aS treatment alone, co-culture with MSCs, or MK-801
treatment (n = 3 per group). Scale bar represents 10 mm.
(H and I) Western blot for NR2A (H) and immunostaining of NR2A that is co-localized with aS (I) after either aS treatment alone, co-culture with MSCs, or MK-801
treatment (n = 3 per group). Scale bar represents 10 mm.
(J) The membrane and cytosol lysates that were immunoprecipitated with anti-NR1 or NR2A and then immunoblotted with anti-aS. The blots reprobed with anti-
NR1 or NR2A antibody to illustrate that relatively equivalent amounts of NMDA receptor were expressed among the groups (n = 3 per group).
All data are presented as means ± SE. *p < 0.05; **p < 0.01.Meanwhile, there was no direct interaction between Gal-1 and
a-synuclein (Figure S3A). Additionally, we compared the pat-
terns of cytokines between MSC-CM and Gal-1 siRNA-treated
MSC-CM in a-synuclein-treated SH-SY5Y cells to evaluate
whether siRNA Gal-1 of MSC abrogates the immunomodula-
tory effects. The pro-inflammatory cytokine levels of interleukin
(IL)-6, chemokine ligand 2 (CCL2), vascular endothelial growth
factor (VEGF), and interferon (IFN)-g and the anti-inflammatory
cytokine levels of IL-4, IL-10, hepatocyte growth factor (HGF),
and transforming growth factor (TGF)-b1 did not differ between
the MSC-CM and siRNA Gal-1-treated MSC-CM groups
(Figure S3B).CShort-Term Effects of MSCs on Transmission of
Extracellular a-Synuclein in a-Synuclein-Inoculated
Animals
Following stereotaxic inoculation of Alexa Fluor 488-labeled
a-synuclein fibrils into the cortex of mice (Figures S4A and
S4C), we examined internalized a-synuclein that was detected
as fluorescent punctate within the cytoplasm at 7 days after
a-synuclein inoculation. The immunoreactivity of a-synuclein
was more densely observed in the cortical areas neighboring
the inoculation site and extensively detected from the ipsilateral
cortex to the contralateral hemisphere (Figure 5A). However,
MSC treatment markedly decreased the density of internalizedell Reports 14, 835–849, February 2, 2016 ª2016 The Authors 839
Figure 4. Gal-1 Plays an Important Role in Transmission Control of Extracellular a-Synuclein
(A and B) 2D-PAGE andMALDI-TOF/MS proteomics approaches fromMSC-CM. On the 2D-PAGE gel of total protein extracted from each medium at 72 hr, spot
intensities and patterns were largely similar between independent samples from the SH-SY5Y-CM group and MSC-CM group. (A) Fresh medium contained 6
discernable polypeptides, SH-SY5Y-CM contained 87 and 96 discernable polypeptides, andMSC-CM contained 189 and 157 discernable polypeptides by silver
staining. (B) The analysis identified 47 spots in MSC-CM that differed significantly by at least 2-fold in expression level compared with fresh or SH-SY5Y-CM. The
area shown in the yellow box in the left panel is enlarged in the right panels. Gal-1 protein is indicated by a yellow circle in enlarged image. A Venn diagram showed
that MSC-CM contained 32 spots, including Gal-1, which were not shared by fresh medium and SH-SY5Y-CM.
(C) Immunostaining for clathrin, EEA1, and surface NR1 and NR2A in SH-SY5Y cells that are co-localized with a-synuclein (aS) in the presence of fresh medium,
MSC-CM, Gal-1 treatment, or Gal-1 siRNA-treated MSC-CM. Scale bar represents 10 mm.
(D)Western blot for clathrin, EEA1, and surface NR1 andNR2A in SH-SY5Y cells after treatmentwith either Gal-1 or Gla-1 siRNA-treatedMSC-CMcomparedwith
fresh medium or MSC-CM (n = 3, each group).
(E) A viability assay in SH-SY5Y cells after aS fibrils were treated with either Gal-1 or Gal-1 siRNA-treatedMSC-CM comparedwith freshmedium orMSC-CM (n =
5, each group).
(F) The membrane and cytosol lysates that were immunoprecipitated with anti-NR1 or NR2A and then immunoblotted with anti-Gal-1 (n = 3 per group).
All data are presented as means ± SE. *p < 0.05; **p < 0.01.a-synuclein in both ipsilateral and contralateral hemispheres
(Figure 5A). Moreover, we examined the immunoreactivity of
phosphorylated a-synuclein to evaluate whether exogenous
a-synuclein induces pathogenic a-synuclein. The phosphory-
lated a-synuclein was exclusively immunostained in the ipsilat-840 Cell Reports 14, 835–849, February 2, 2016 ª2016 The Authorseral and contralateral hemispheres of a-synuclein-inoculated
animals, and this immunoreactivity was observed within neurons
in the cortex (Figure 5B). However, phosphorylated a-synuclein
immunoreactivity was not observed in MSC-treated a-synu-
clein-inoculated animals (Figure 5B). The ELISA analysis showed
Figure 5. Short-Term Effects of MSCs on Extracellular a-Synuclein Transmission
(A) Immunostaining for internalized Alexa Fluor 488-labeled a-synuclein (aS), showing that the density and extent of spreading aS in ipsilateral and contralateral
hemispheres were less prominent in mice receiving MSCs compared with aS alone. Scale bar represents 10 mm. Arrowheads denote labeled aS in the cortical
areas.
(B) The phosphorylated a-synuclein (p-aS) was immunostained within neurons of aS-inoculated ipsilateral and contralateral hemispheres, whereas this
immunoreactivity was not observed in MSC-treated animals. Scale bar represents 10 mm. Arrowheads denote co-localization of Alexa Fluor 488-labeled aS,
p-aS, and neuronal nuclei (NeuN).
(C) Quantification of cytosolic aS using ELISA in ipsilateral and contralateral hemispheres of mice receiving MSCs compared with aS alone (n = 5, per group).
(D) Western blot for p-aS in ipsilateral and contralateral hemispheres of mice receiving MSCs compared with aS alone (n = 5 per group).
(E) Western blot for clathrin, EEA1, NR1 subunit, and NR2A subunit in ipsilateral (I) and contralateral (C) hemispheres of mice receiving MSCs compared with aS
alone (n = 5 per group).
(F andG)Western blot for pro- and cleaved caspase-3 (F) and immunostaining of TUNEL (G) inmice after treatment withMSCs comparedwith aS alone. Scale bar
represents 10 mm.
All data are presented as means ± SE. *p < 0.05; **p < 0.01.
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Figure 6. Treatment with Either MSC-CM or Gal-1 Modulates CME of Extracellular a-Synuclein Fibrils and Reduces the Cell-to-Cell
Transmission
(A) Immunostaining for internalized Alexa Fluor 488-labeled a-synuclein (aS), showing that the density and extent of propagated aS in ipsilateral (I) and
contralateral (C) hemispheres were less prominent in mice receiving MSC-CM or Gal-1. Scale bar represents 10 mm. Arrowheads denote Alexa Fluor 488-labeled
aS in the cortical areas neighboring the inoculation site.
(B) Immunostaining of Alexa Fluor 488-labeled aS and phosphorylated a-synuclein (p-aS) within neurons of ipsilateral and contralateral hemispheres were less
prominent in treatment with either MSC-CM or Gal-1 compared with fresh medium (Fresh). Scale bar represents 10 mm. Arrowheads denote co-localization of
Alexa Fluor 488-labeled aS, p-aS, and NeuN.
(C) Quantification of cytosolic aS using ELISA in ipsilateral and contralateral hemispheres of mice receiving MSC-CM or Gal-1 (n = 5 per group).
(D) Western blot for p-aS in ipsilateral and contralateral hemispheres of mice receiving MSC-CM or Gal-1 (n = 5 per group).
(legend continued on next page)
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that MSC treatment in a-synuclein-treated mice significantly
attenuated the expression of cytosolic a-synuclein in both the
ipsilateral and contralateral hemispheres compared with that in
mice treated with a-synuclein alone (Figure 5C). In addition,
MSC treatment in a-synuclein-inoculated brain significantly
attenuated phosphorylated a-synuclein expression (Figure 5D).
Next, we examined whether MSC administration modulates
CME of extracellular a-synuclein fibrils through the modulation
of surface NMDA receptors. An inoculation of a-synuclein fibrils
led to increased expression of clathrin in both the ipsilateral
and contralateral hemispheres of inoculation, whereas MSC
treatment significantly attenuated expression of this protein
(Figure 5E). Immunohistochemical analysis showed that MSC
treatment led to a decrease in the immunoreactivity of labeled
a-synuclein and clathrin in both the ipsilateral and contralateral
hemispheres (Figure S5). As a result of CME inhibition, MSC
administration in a-synuclein-inoculated mice significantly
decreased expression of EEA1 (Figure 5E) and the immunoreac-
tivity of labeled a-synuclein and EEA1 in both the ipsilateral and
contralateral hemispheres (Figure S5). Additionally, MSC admin-
istration led to a significant increase in the expression of a-syn-
uclein-induced surface NR1 and NR2A subunits (Figure 5E) and
a decrease in the immunoreactivity of surface NR1 and NR2A
subunits that were co-localized with a-synuclein (Figure S5) in
both the ipsilateral and contralateral hemispheres of a-synu-
clein-inoculated mice. Consequently, a-synuclein inoculation
led to markedly increased expression of cleaved caspase-3
and the immunoreactivity of terminal deoxynucleotidyltransfer-
ase-mediated dUTP nick end labeling (TUNEL) in the ipsilateral
hemisphere relative to controls; however, MSC treatment
notably decreased the expression of cleaved caspase-3 and
the number of TUNEL-positive neurons (Figures 5F and 5G). To
exclude microglial effects on a-synuclein modulation via micro-
glial clearance of a-synuclein fibrils, we further analyzed the
short-term effects of MSC on a-synuclein propagation in a-syn-
uclein-inoculated animals by using both M1 and M2 microglia
depletion conditions. MSC treatment in microglia depletion
conditions markedly decreased the immunoreactivities of inter-
nalized a-synuclein and phosphorylated a-synuclein in both
the ipsilateral and contralateral hemispheres with a significant
decrease in the expression of cytosolic a-synuclein and phos-
phorylated a-synuclein (Figure S6). This indicates that the effect
of MSC on a-synuclein propagation may not be mediated by
immunomodulation but rather the consequence of a direct inhi-
bition of a-synuclein transmission.
Transmission of Extracellular a-Synuclein Is Decreased
by Gal-1 in a-Synuclein-Inoculated Animals
We evaluated whether Gal-1 can modulate a-synuclein trans-
mission in a-synuclein-inoculated animals. Inhibition of a-synu-
clein propagation was similarly observed following MSC-CM
or Gal-1 treatment (Figure 6A). Additionally, MSC-CM or Gal-1(E) Western blot for clathrin, EEA1, NR1 subunit, and NR2A subunit in ipsilateral
group).
(F–H) Western blot for pro- and cleaved caspase-3 (F) and immunostaining of
represents 10 mm.
All data are presented as means ± SE. *p < 0.05; **p < 0.01.
Ctreatment markedly decreased the immunoreactivity of phos-
phorylated a-synuclein in the ipsilateral and contralateral hemi-
spheres of a-synuclein-inoculated animals (Figure 6B). The
ELISA analysis confirmed that the expression of cytosolic and
phosphorylated a-synuclein was significantly decreased in the
ipsilateral and contralateral hemispheres following MSC-CM or
Gal-1 (Figures 6C and 6D). MSC-CM or Gal-1 treatment signifi-
cantly attenuated clathrin expression (Figure 6E) and immunore-
activity (Figure S5) in both the ipsilateral and contralateral hemi-
spheres of inoculation, which was accompanied by decreased
expression of EEA1 (Figure 6E) and the immunoreactivity of
labeled a-synuclein and EEA1 (Figure S5). MSC-CM or Gal-1
treatment inhibited the CME of extracellular a-synuclein fibrils
through modulation of surface NMDA receptors; however,
Gal-1 treatment did not show a significant interaction with the
surface NR2A subunit (Figure 6E). In addition, we evaluated
whether siRNA Gal-1 of MSC could influence microglia polariza-
tion to exclude microglial clearance of a-synuclein as much as
possible. The levels of IL-1b (an M1 marker) and arginase 1 (an
M2 marker) did not differ significantly between the MSC-CM
and siRNAGal-1-treatedMSC-CM groups (Figure S7A). Further-
more, we showed that CD105 siRNA-treated MSC-CM did not
change the immunoreactivity and expression patterns of phos-
phorylated a-synuclein compared to the MSC-CM treatment,
indicating that CD105 released by MSCs does not influence
a-synuclein phosphorylation (Figures S7B and S7C). Conse-
quently, MSC or Gal-1 treatment notably decreased the expres-
sion of cleaved caspase-3 and the number of TUNEL-positive
neurons in a-synuclein-inoculated animals (Figures 6F–6H).
Long-Term Effects of MSCs on Transmission of
Extracellular a-Synuclein in a-Synuclein-Inoculated
Animals
Following stereotaxic inoculation of Alexa Fluor 488-labeled
a-synuclein fibrils into the dorsal striatum of mice (Figures S4B
and S4D), we assessed dopaminergic neuronal loss in the sub-
stantia nigra (SN) of the midbrain and behavioral deficits at
30 days after a-synuclein inoculation. a-Synuclein inoculation
in the striatum markedly increased the immunoreactivity of the
phosphorylated form of a-synuclein in the midbrain (Figure 7A)
and dopaminergic neurons (Figure 7B), which was accompanied
by a significant decrease in the number of tyrosine hydroxylase
(TH)-positive neurons in the SN (Figure 7C). On behavioral
analysis, a-synuclein inoculation led to progressive patterns of
the latency to fall on the Rotarod test and increased latency to
descend on the latency to fall test at 30 days after a-synuclein
inoculation compared to the control group (Figure 7D). How-
ever, MSC treatment in a-synuclein-inoculated animals signifi-
cantly attenuated the immunoreactivity of the phosphorylated
form of a-synuclein in themidbrain (Figure 7A) and dopaminergic
neurons (Figure 7B). Moreover, MSC treatment significantly
decreased dopaminergic neuronal loss in the SN (Figure 7C)and contralateral hemispheres of mice receiving MSC-CM or Gal-1 (n = 5 per
TUNEL (G and H) in mice after treatment with MSC-CM or Gal-1. Scale bar
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and led to the restoration of impaired motor coordination and
balance on the Rotarod test and pole test (Figure 7D). In addition,
phosphorylated a-synuclein was observed in the striatal areas
neighboring the inoculation site and was extensively detected
in the bilateral parietal and entorhinal cortices at 30 days after
a-synuclein inoculation (Figure 7E). However, MSC treatment
significantly attenuated the immunoreactivity of phosphorylated
a-synuclein in these areas (Figure 7E).
DISCUSSION
The present study demonstrated that MSCs have inhibited prop-
agation of a-synuclein via modulation of its transmission by
inhibiting NMDA-receptor-mediated endocytosis, which led to
a prosurvival effect on neurons with functional improvement of
motor deficits in a-synuclein-enriched models. In addition, we
found that Gal-1, soluble factor derived from MSCs, plays an
important role in transmission control of extracellular a-synuclein
via competing with a-synuclein for NMDA receptor binding in
these models. Our data suggest that the property of MSCs in
modulating the propagation of extracellular a-synuclein may be
applicable to future clinical strategies for treatment of patients
with a-synucleinopathies.
a-Synuclein has a tendency to aggregate and accumulate,
thus forming small intracellular aggregates, which could lead
to an increase in cellular toxicity and cell death in various types
of a-synucleinopathies (Conway et al., 1998; Uversky et al.,
2001a). Importantly, recent studies have provided evidence for
cell-to-cell propagation of a-synuclein (Lee et al., 2010b,
2014), showing that a-synuclein and its aggregates are released
from neuronal cells via exocytosis (Lee et al., 2005, 2014; Li et al.,
2008) and that neurons and glial cells have the ability to inter-
nalize extracellular a-synuclein aggregates through endocytosis
(Desplats et al., 2009; Guo and Lee, 2014; Lee et al., 2010a). In
terms of their prion-like behavior, extracellular a-synuclein ag-
gregates seem to play key roles in the pathogenesis and pro-
gression of a-synucleinopathies; therefore, treatment strategies
that are focused on the modulation of extracellular a-synuclein
transmission would be clinically relevant. In this regard, the re-
sults of immunotherapy in animal models of Lewy body diseases
are very suggestive, because antibodies against a-synuclein can
modulate aggregated a-synuclein at several steps of accumula-
tion and propagation (Bae et al., 2012; Fagerqvist et al., 2013;
Masliah et al., 2011; Tran et al., 2014; Valera and Masliah,
2013). Therefore, a therapeutic strategy to inhibit propagationFigure 7. Long-Term Effects of MSCs on Extracellular a-Synuclein Tra
(A) The immunoreactivity of phosphorylated form of a-synuclein (p-aS) in the m
treated animals compared to a-synuclein (aS)-inoculated animals. Scale bar repre
with p-aS.
(B) The immunoreactivity of p-aS in the TH-positive neurons of the SNwasmarked
bar represents 10 mm. Arrowheads denote co-localization of TH with p-aS.
(C) The number of TH-positive neurons in the SN at 30 days (d) after aS inoculat
(D) Behavioral analysis, showing that aS inoculation led to progressive patterns
30 days after aS inoculation on fall test compared to the control group, whereasMS
test and pole test (n = 5 per group).
(E) The distribution of p-aS accumulations in the striatum, parietal cortex, and en
icantly attenuated the immunoreactivity of p-aS in these areas. Scale bar repres
All data are presented as means ± SE. *p < 0.05; **p < 0.01.
Cof extracellular a-synuclein aggregates may be an important
pharmacological target in disease-modifying treatment strate-
gies for a-synucleinopathies.
Several studies have demonstrated that MSCs exert neuro-
protective effects by secretion of neurotropic molecules that
directly or indirectly can modulate neurodegenerative microen-
vironment (Mathieu et al., 2012; Paul and Anisimov, 2013).
Importantly, even though the underlying mechanisms of MSCs
seem to differ depending on disease entity or animal models of
parkinsonian diseases, MSCs could exert a neuroprotective
effect on dopaminergic neurons by autophagic modulation of
a-synuclein in the mitochondrial-neurotoxin-induced PD model
and immunomodulation (Park et al., 2014; Stemberger et al.,
2011). Here, we found that MSCs have the ability to inhibit a-syn-
uclein endocytosis and lead to the inhibition of a-synuclein
transmission. In an a-synuclein-enriched cellular model, MSCs
inhibited the internalization of extracellular a-synuclein and
decreased the transmission of a-synuclein in a donor-acceptor
model. As a result, MSCs significantly decreased the levels of
internalized cytosolic a-synuclein and led to attenuation in
a-synuclein-induced cell death. Specifically, we demonstrated
that MSCs can inhibit the CME of extracellular a-synuclein fibrils
via modulation of interaction between a-synuclein and NMDA
receptors. a-Synuclein treatment led to increased expression
of clathrin and EEA1, with a concomitant decrease in the immu-
noreactivity of surface NR1 and NR2A subunits. Meanwhile,
MSC treatment significantly attenuated the a-synuclein-induced
expression of clathrin and EEA1, as well as an interaction be-
tween a-synuclein and NMDA receptors. In an animal model of
a-synuclein inoculation, MSC treatment markedly decreased
the transmission of extracellular a-synuclein regions of the brain
at a distance from the inoculation site. When a-synuclein was
inoculated in the cortex, MSC treatment markedly decreased
the density of internalized a-synuclein and the pathogenic
phosphorylated form of a-synuclein in both the ipsilateral and
contralateral hemispheres. Moreover, MSC administration in
a-synuclein-inoculated mice significantly decreased the expres-
sion of clathrin, which was followed by decreased expression of
EEA1 and an interaction between a-synuclein and NMDA recep-
tors of NR1 and NR2A. Additionally, when a-synuclein was
inoculated in the striatum, MSC treatment decreased the phos-
phorylated form of a-synuclein expression in the midbrain at
30 days after inoculation. Consequently, modulation of extracel-
lular a-synuclein propagation by MSCs led to the exertion of a
prosurvival effect on cortical neurons and nigral dopaminergicnsmission
idbrain, showing that p-aS immunoreactivity was markedly attenuated MSC-
sents 10 mm. Arrowheads denote co-localization of Alexa Fluor 488-labeled aS
ly attenuatedMSC-treated animals compared to aS-inoculated animals. Scale
ion. L, left; R, right. Scale bar represents 10 mm.
of the latency to fall on the Rotarod test and increased latency to descend at
C treatment restored impairedmotor coordination and balance on theRotarod
torhinal cortex, showing that MSC treatment in aS-inoculated animals signif-
ents 10 mm.
ell Reports 14, 835–849, February 2, 2016 ª2016 The Authors 845
neurons, with functional improvement of impaired motor coordi-
nation and balance against an a-synuclein-enriched environment.
Interestingly, we demonstrated in the present study that the
MSC-derived factor, Gal-1, could inhibit transmission of a-synu-
clein through competition with a-synuclein for NMDA receptor
binding, leading to reduced endocytosis and thus lower a-synu-
clein entry. Gal-1, a galactose-binding lectin, is a multifunctional
molecule involved in the regulation of cell adhesion, cell prolifer-
ation, and programmed cell death (Perillo et al., 1998). In the ner-
vous system, Gal-1 is involved in the proliferation of neural stem
cells, neritic outgrowth, and cellular adaptation of redox status
(Lekishvili et al., 2006;Miura et al., 2004), aswell as the regulation
of glutamate toxicity via interaction with the NR1 subunit (Lekish-
vili et al., 2006). In an a-synuclein-enriched cellular model, Gal-1
treatment significantly decreased the expression of clathrin and
EEA1 and increased the expression of NR1, with a concomitant
increase in NMDA receptor binding, which led to decreased
levels of internalized cytosolic a-synuclein. This modulatory
effect of Gal-1 on transmission of aggregated a-synuclein was
further supported by Gal-1 siRNA treatment in vitro, showing
that siRNA counteracted the inhibitory effect of MSCs on
CME of a-synuclein via NMDA receptors and its associated
prosurvival effects on SH-SY5Y cells. In vivo data showed
that Gal-1 was co-expressed within MSCs injected intrave-
nously and that Gal-1 treatment blocked CME of extracellular
a-synuclein fibrils by inhibiting interaction of a-synuclein and
surface NMDA receptors. In animals treated with enriched
a-synuclein, this modulatory effect of Gal-1 on membrane traf-
ficking of a-synuclein seemed to be comparable to those of
MSCs by showing that Gal-1 treatment markedly decreased
the extent of inoculated a-synuclein aggregates, as well as
expression of the pathological a-synuclein, compared to fresh
medium. In this regard, the present study provides evidence
that Gal-1, as an MSC-derived soluble factor, can modulate
the pathogenic microenvironments of extracellular a-synuclein
via modulation of CME.
Although the exact mechanism contributing cell-to-cell trans-
mission of a-synuclein is unknown, several possible routes
mediated by direct penetration, fluid-phase, or receptor-medi-
ated endocytosis, the form of exosome, or nanotube have
been suggested depending on the forms of a-synuclein. Of
those, receptor-mediated endocytosis, which requires specific
interactions between ligands and cell-surface receptors, seems
to be a major mode of fibril internalization (Guo and Lee, 2014).
Along with evidence of a-synuclein participation in CME (Cheng
et al., 2011), several studies suggested that forms of a-synuclein
with a higher molecular weight, such as aggregated fibrillar or
oligomeric forms, may be internalized through an endocytic
pathway via receptor (Chai et al., 2013; Cheng et al., 2011; Lee
et al., 2008, 2010b, 2014). Moreover, other studies have shown
that the receptor-mediated endocytosis is also involved in
amyloid-b transmission. Amyloid-b could decrease the surface
expression of NMDA receptors by promoting endocytosis of re-
ceptor proteins (Sakono and Zako, 2010; Snyder et al., 2005),
which is quite in accordance with the present result. Additionally,
the laminin receptor has a central role in mediating the internal-
ization of amyloid-b (Da Costa Dias et al., 2014). Taken together,
the present data indicate that MSCs have a prosurvival effect846 Cell Reports 14, 835–849, February 2, 2016 ª2016 The Authorson cortical and dopaminergic neurons against propagation of
a-synuclein by modulating a major route of transmission of toxic
protein aggregates. However, the data in the present study do
not directly support themodulatory effect ofMSCs on cell-to-cell
transmission, as our in vitro experiment does not fully address
aggregated a-synuclein in cellular systems.
According to our in vitro data, the modulatory effect of MSCs
on extracellular a-synuclein and their prosurvival effects on
SH-SY5Y cells were not completely blocked by Gal-1 siRNA-
treated CM. Additionally, even though MSCs significantly inter-
acted with both NR1 and NR2A subunits, Gal-1 treatment did
not show a significant interaction with the surface NR2A subunit.
These results suggest the existence of other MSC-derived
soluble factors involved in aggregated a-synuclein transmission.
Therefore, further studies are required to identify the MSC-
derived small molecules or exosomes responsible for extracel-
lular a-synuclein modulation that would have clinical potential
for the development of disease-modifying therapeutic strategies
for a-synucleinopathies.
In summary, the present data indicated that MSCs exert
neuroprotective properties through inhibition of extracellular
a-synuclein transmission. In addition, Gal-1 may be the principal
soluble factor released by MSCs responsible for modulation of
extracellular a-synuclein. With advantages in clinical applica-
tions (Bang et al., 2003; Lee et al., 2012a), the use of MSCs
or MSC-derived soluble factors as pharmacological modula-
tors of a-synuclein propagation may be an effective therapeutic
approach.
EXPERIMENTAL PROCEDURES
MSCs and SH-SY5Y Culture
Frozen vials of characterized human MSCs at passage 2 were obtained from
the Severance Hospital Cell Therapy Center. The human neuroblastoma cell
line, SH-SY5Y, was obtained from the Korean Cell Line Bank. Both MSCs
and SH-SY5Y cells were maintained in DMEM (HyClone) supplemented with
10% fetal bovine serum (HyClone) and an antibiotic mixture of penicillin and
streptomycin (1%, HyClone). When these cells reached 70%–80% conflu-
ence, they were trypsinized and subcultured. These cells were cultivated in
a humidified incubator at 37C and 5% CO2 before use. For differentiation,
SH-SY5Y cells were plated at a density (of 53 105/cm2) and grown as amono-
layer in DMEM. One day after plating, the cells were incubated in fresh DMEM
with 10 mM retinoic acid (Sigma). The medium was changed on alternate days,
and cultures were allowed to differentiate for 2 weeks (Lopes et al., 2010) and
were then treated with a-synuclein (1 mM) or Gal-1 (100 ng) for 2 hr. Addition-
ally, the effects of MSCs were tested in differentiated SH-SY5Y that were co-
cultured without direct contact using a Costar transwell (Corning). The MSCs
were cultured on the permeable membrane of a Costar transwell insert, and
the differentiated SH-SY5Y cells were maintained on the bottom of a plate.
For inhibition of a-synuclein clearance, bafilomycin A1 (50 nM, Sigma) was
added to the medium containing a-synuclein. For inhibition of endocytosis
and NMDA receptors, dynasore (80 mM, Sigma) and MK-801 hydrogen male-
ate (50 mM, Sigma) were pre-treated to the replacement medium for 3 hr.
Finally, Pitstop 2 (30 mM, Abcam) was pre-treated to the replacement medium
for 10min to inhibit CME, and as a selective NR1/NR2A receptor inhibitor (Han-
sen et al., 2012), TCN 201 (50 mM, Tocris) was pre-treated to the replacement
medium for 3 hr. All experiments were replicated three times.
BiFC System
SH-SY5Y cells were transfected with Venus1-a-synuclein or a-synuclein-
Venus2 (Bae et al., 2014) using electroporation. The stable cell lines were
maintained with 200 mg/ml G418 (Invitrogen).
Preparation of Cell CM
CM were prepared as follows: 80% confluent MSCs at passage 5 and
SH-SY5Y cells were fed with serum-free DMEM for 72 hr. The media of
MSCs and SH-SY5Y cells were both assumed to contain various paracrine
molecules. These media were collected. For in vivo injection, CM from 1 3
106 cells were centrifuged to remove cell debris and concentrated using
VIVASPIN6 centrifugal filter devices (Sartorius Stedim) at 4C for 1 hr. These
media were stored frozen.
Cell Viability Analysis
Differentiated SH-SY5Y cells were harvested and plated in 24-well polystyrene
plates (Corning) at 1.5 3 105 cells. Plates were incubated at 37C for 24 hr to
allow cells to attach. After 24 hr, SH-SY5Y cells were directly treated with
a-synuclein. The same volume of DMEM was added to the control cultures.
Plates were then incubated at 37C for an additional 3 hr, 24 hr, and 48 hr.
Cell viability was measured by trypan blue exclusion assays. Briefly, after
the cells were incubated with the various medium samples, SH-SY5Y cells
were washed with PBS and trypsinized, and then 10 ml of cells were added
to the trypan blue and mixed thoroughly. The viable cells were counted using
a Countess automated cell counter (Invitrogen). The mean value of Ki67-nega-
tive cells in randomly five chosen fields was calculated by respectively count-
ing using the 403 magnification objective lens. Values of cell viability were
expressed as calculated number of Ki67-negative cells counted/total cells
counted 3 100 = a percentage of viability. All experiments were repeated at
least three times.
Animal Study
All procedures were performed in accordance with the Laboratory Animals
Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the
Guidelines and Policies for Rodent Experimentation provided by the Institu-
tional Animal Care and Use Committee (IACUC) at the Yonsei University Health
System. Male C57BL/6 mice (Orient Bio) were acclimated in a climate-
controlled room with a constant 12 hr/12 hr light/dark cycle for 1 week prior
to the initiation of drug administration. At 6 weeks of age, a-synuclein (5 mg
per mouse) was administered via the neocortex. Cortical administration was
carried out in accordance with the procedure described previously, with minor
modifications (Hansen et al., 2011). Briefly, mice were anesthetized with iso-
flurane (Baxter), and a-synuclein was slowly injected bilaterally into the cortex
(0.4 mm posterior to bregma,1.3 mm lateral to midline, and0.6 mm ventral
to the brain surface) using a stainless steel (26-gauge) injection needle con-
nected to a 10-ml microsyringe (Hamilton). The needle was left in place for
10 min before being withdrawn slowly. To evaluate the short-term effects of
MSCs on a-synuclein transmission, the mice were randomly divided into three
groups (n = 5 per group): (1) control; (2) a-synuclein; and (3) a-synuclein and
MSC. Control mice were injected with saline via tail vein at 1 day after a-syn-
uclein inoculation (postoperative day 1). Mice in the MSC group were sub-
jected to MSCs into the tail vein (1 3 106 cells per 200 ml) on postoperative
day 1. All micewere sacrificed on postoperative day 7. Additionally, to evaluate
the modulation of a-synuclein transmission by MSC-CM or Gal-1, the mice
were randomly divided into six groups (n = 5 per group): (1) control; (2) fresh
medium; (3) MSC-CM; (4) Gal-1; (5) Gal-1 siRNA-CM; and (6) CD105 siRNA-
CM. Mice in the each group were subjected to medium delivery on postoper-
ative day 1, and all mice were sacrificed on postoperative day 7. Finally, to
evaluate the long-term effects of MSCs on a-synuclein transmission, the
mice were randomly divided into three groups (n = 5 per group): (1) control;
(2) a-synuclein; and (3) a-synuclein and MSC. a-Synuclein was slowly injected
into the striatum (0.2 mm posterior to bregma, ±2.0 mm lateral to midline, and
2.6 mm ventral to the brain surface). Mice in the MSC group were subjected
to MSCs into the tail vein (13 106 cells per 200 ml) on postoperative day 1 and
postoperative day 10. All mice were sacrificed on postoperative day 30.
Depletion of M1 or M2 Microglia
Microglia depletion was carried out in accordance with the procedure
described previously, with a minor modification (Lee et al., 2012b; Miron
et al., 2013). Gadolinium chloride (Sigma) and mannosylated-clodronate-
encapsulated liposomes (Encapsula Nano Sciences) were applied to produce
the M1 and M2 microglia depletion conditions, respectively. Gadolinium chlo-Cride (270 mM) was stereotaxically injected into the cerebral ventricle (0.2 mm
posterior to bregma, 1.0 mm lateral to midline, and 3.0 mm ventral to the brain
surface) of mice, followed by stereotaxic injection of clodronate liposomes
(270 mM) into the cerebral ventricle. Next, a-synuclein was slowly injected
into the cortex on postoperative day 5.
Immunoprecipitation Assay
Membrane or cytosol lysates were obtained as described in the Supplemental
Experimental Procedures. NR1, NR2A, and Gal-1 antibodies were added to
1 mg of lysates and incubated for 4 hr at 4C. Protein G agarose beads (Invi-
trogen) were added and incubated for overnight at 4C. Then, the lysates were
spun at 14,0003 g, the pelleted protein G agarose was washed by lysis buffer
five times, and the pellet was resuspended with 20 ml 23 SDS sample buffer
and subjected to SDS-PAGE and western blot analysis with a-synuclein
antibody.
Measurement of a-Synuclein
The amount of a-synuclein was measured using a sandwich ELISA kit
(AnaSpec). 10 ml of each diluted sample, and standards included in the kit
were applied to microtiter plates precoated with antibody that specifically
recognized a-synuclein. Following an overnight incubation at 4C and
washing, a detection antibody indirectly linked to an enzyme was applied.
After incubation and washing, 350 ml of wash solutions were added to
each well and then the plate was inverted and dried by hitting the plate until
no moisture appears. The substrate was added and incubated for 15 min at
37C, and then the reaction was stopped with stop solution. The color reac-
tion was measured with an automatic ELISA microplate reader (BioTek
Instruments), with the wavelength set at 450 nm. The software (Bio-Rad)
was used to create standard curves and to calculate the concentration of
the samples.
Cytokine Analysis in MSC-CM
MSC-CM and Gal-1 siRNA-treated MSC-CM were assayed in duplicate using
specific ELISA kits for human IL-4, IL-6, IL-10, HGF, CCL2, TGF-b1, VEGF,
and IFN-g, respectively (R&D Systems). The optical density of each well
was read at 450 nm and corrected at a wavelength of 540 nm according to
the manufacturer’s instructions with an automatic ELISA microplate reader
(BioTek Instruments). The final concentration was calculated by converting
the optical density readings against a standard curve.
Additional Procedures
Please refer to the Supplemental Experimental Procedures for details on
a-synuclein aggregate fluorescent dye labeling, plasmid transfections,
2D-PAGE, MALDI-TOF/MS analysis, RT-PCR, brain sample preparation,
immunocytochemistry, immunohistochemistry, western blotting analysis, ro-
tarod test, pole test, TUNEL assay, and stereological cell counts.
Statistical Analysis
The groupmeans were compared using theMann-Whitney U test for pairs and
the Kruskal-Wallis analysis for multiple groups. p values less than 0.05 were
considered statistically significant. Statistical analyses were performed using
commercially available software (version 12.0; SPSS).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.12.075.
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